Merck & Co., Inc. — Director's Dealing 2021

May 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2021-05-10

Reporting Person: Clyburn Frank (EVP & Pres ? Human Health)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-10	Common Stock	M	19324	—	Acquired	113672.057	Direct
2021-05-10	Common Stock	S	19324	$78.3192	Disposed	94348.057	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-10	Stock Option (Right to Buy)	$44.98	M	19324	Disposed	2023-05-05	Common Stock (19324)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock - 401(k) Plan	1753.3913	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $78.42, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2: Holdings include shares acquired in dividend reinvestment transactions.

F3: Includes shares acquired and dividends earned through April 7, 2021 in the Merck U.S. Savings Plan, a 401(k) plan.

F4: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.